Adjuvant Chemotherapy Versus Chemoradiation for Patients with Resected Pancreatic Adenocarcinoma: A Single-Center Retrospective Study.
10.15279/kpba.2018.23.3.108
- Author:
Do Young KIM
1
;
Young Jin CHOI
;
Young Mi SEOL
;
Hyojeong KIM
Author Information
1. Department of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea. leonkim80@naver.com
- Publication Type:Original Article
- Keywords:
Pancreatic cancer;
Chemotherapy;
Chemoradiotherapy;
Adjuvant
- MeSH:
Adenocarcinoma*;
Busan;
Chemoradiotherapy;
Chemotherapy, Adjuvant*;
Drug Therapy;
Humans;
Medical Records;
Pancreatic Neoplasms;
Prognosis;
Retrospective Studies*;
Survival Rate
- From:Korean Journal of Pancreas and Biliary Tract
2018;23(3):108-115
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: This study aimed to compare the outcomes of patients who received systemic chemotherapy or chemoradiotherapy as adjuvant therapies following pancreatic adenocarcinoma resection. METHODS: We reviewed the medical records of 40 patients with locoregional pancreatic adenocarcinoma who underwent tumor resection at Pusan National University Hospital between 2008 and 2012. RESULTS: Twenty-nine patients were treated with adjuvant therapy comprising either systemic chemotherapy or chemoradiotherapy after curative-intent surgery. Adjuvant therapy (p=0.025) and complete resection (p=0.043) were associated with longer overall survival. There was no significant difference between chemotherapy and chemoradiotherapy in terms of extending overall survival; however, patients who received chemotherapy had significantly higher survival rates than those who received no adjuvant therapy at all (p=0.012). CONCLUSIONS: Adjuvant therapies improve the prognoses of patients with resected pancreatic adenocarcinoma; moreover, chemotherapy produced more favorable outcomes than chemoradiotherapy.
